Public Health, Prevention & Behaviour Change
Current research into psychedelics as a means of public health intervention highlights their potential in addressing various behavioural health conditions. As clinical trials expand, the implications for prevention and behaviour change are becoming increasingly apparent.
Key Insights
- 1
Psychedelics have been observed to create lasting changes in behaviour and emotional regulation, which are promising for therapeutic interventions.
- 2
Current psychedelic research largely involves observational and retrospective studies, necessitating more robust randomised clinical trials.
- 3
Public health approaches incorporating psychedelics are rapidly evolving, with potential to address equity in mental health treatment access.
What is Public Health, Prevention & Behaviour Change?
Public health encompasses the study of health promotion, disease prevention, and behaviour change at a population level, focusing on improving health outcomes.
Behavioural health conditions, including substance use disorders and mental health issues, can be influenced significantly by social and environmental factors that require community-level interventions.
Emerging evidence suggests that psychedelics, including compounds such as psilocybin and MDMA, may play a role in enhancing therapeutic approaches to address these conditions through their effects on emotional and cognitive processes.
Current Treatments
Standard-of-care treatments for behavioural health conditions typically include psychotherapy, cognitive-behavioural therapies, and pharmacological interventions such as antidepressants and anti-anxiety medications.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Public Health, Prevention & Behaviour Change.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Numerous clinical trials demonstrate psilocybin's efficacy in treating major depression and anxiety associated with terminal illness. | Large | High | Consistent |
| MDMA Multiple phase 3 trials support MDMA-assisted therapy for PTSD, showing marked improvement in clinical outcomes. | Large | High | Highly Consistent |
| LSD Some studies suggest LSD can enhance creative problem-solving and emotional processing, though robust evidence is still pending. | Medium | Moderate | Inconsistent |
| Ayahuasca There are promising results regarding Ayahuasca's potential to facilitate psychological insights and behavioural change, but evidence remains early-stage. | Medium | Moderate | Inconsistent |
| Ketamine Ketamine has shown rapid antidepressant effects in treatment-resistant depression, supporting its therapeutic potential. | Large | High | Consistent |
Psilocybin and Public Health, Prevention & Behaviour Change
Psilocybin, the active compound in magic mushrooms, has been shown to produce profound changes in perception, mood, and cognition. Research indicates that it can facilitate therapeutic breakthroughs in behavioural health by enabling patients to re-examine their life perspectives, thereby aiding in the treatment of anxiety, depression, and addiction.
MDMA and Public Health, Prevention & Behaviour Change
MDMA, commonly known as ecstasy, has therapeutic applications in PTSD treatment. It enhances emotional engagement and decreases fear response, allowing patients to revisit trauma in a safe, guided therapeutic setting. This compound has undergone extensive study, resulting in consistent improvements in clinical outcomes for individuals suffering from trauma-related conditions.
Ketamine and Public Health, Prevention & Behaviour Change
Ketamine, traditionally an anaesthetic, has emerged as a fast-acting antidepressant for individuals with severe depression. Its mechanism of action appears to involve the modulation of glutamate, leading to synaptic plasticity and rejuvenation of neural connections, contributing to lasting behavioural change.
Clinical Outlook
The future of psychedelic treatments in public health signifies a paradigm shift, as continued research focuses on integrating these compounds into standard treatment modalities. With rigorous clinical trials validating their efficacy and safety, psychedelics may reshape preventative strategies and therapeutic frameworks for behavioural health conditions, thereby enhancing public health outcomes.
Industrial Landscape
Key players in the research and implementation of psychedelics include academic institutions, non-profit organisations focused on mental health, and pharmaceutical companies exploring the therapeutic potentials of psychedelic compounds.
Quick Indicators
Organisations
Search →AtaiBeckley
Clinical-stage psychedelic company that also functions as a strategic-corporate capital allocator through legacy atai platform investments and deal activity in the sector.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Imperial College London
The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
University of Ottowa
The University of Ottawa launched a groundbreaking one-year MA in Psychedelics and Consciousness Studies in 2024, jointly offered by the Faculty of Social Sciences and Faculty of Arts under co-directors Dr. Monnica Williams and Dr. Anne Vallely. The program builds on earlier microprograms in Psychedelic Science and Psychedelics & Spirituality Studies established since 2020, training licensed professionals, clergy, and researchers in therapeutic, spiritual, and academic dimensions of psychedelics.
King's College London
The Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.
Federal University of Rio Grande do Norte (UFRN)
Federal University of Rio Grande do Norte is a public research university in Brazil with active neuroscience and mental health research programmes, including work linked to psychedelic science through affiliated institutes.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Amsterdam UMC (AMC-UvA) is one of the leading academic medical centers in the Netherlands, uniting the medical faculties of the University of Amsterdam and Vrije Universiteit Amsterdam with extensive clinical and translational research programs. The center has participated in psychedelic research including psilocybin microdosing studies, contributing to the Netherlands' growing academic investigation of psychedelic-assisted therapy.
Canadian Forces Health Services Centre Ottawa
The Canadian Forces Health Services Centre Ottawa is the primary military healthcare facility serving the National Capital Region, providing comprehensive medical, mental health, and occupational health care to Canadian Armed Forces (CAF) personnel and their families. The centre supports CAF members with psychiatric services relevant to trauma and PTSD, areas in which the Canadian military has shown growing interest in ketamine-based and psychedelic-assisted therapies as emerging treatment options.
Sheba Medical Center
Israel's largest hospital and a major academic medical center affiliated with Tel Aviv University. A key site for MDMA-assisted psychotherapy trials through MAPS Israel and other research programs, as well as ketamine studies for treatment-resistant depression.
UMC Utrecht
The University Medical Center Utrecht is a major academic hospital affiliated with Utrecht University in the Netherlands. One of the largest hospitals in the Netherlands, UMC Utrecht integrates top-level patient care, medical education, and clinical research across specialties including psychiatry, neurology, oncology, and cardiovascular medicine.
Utrecht Institute for Pharmaceutical Sciences
A research institute within Utrecht University's Faculty of Science in the Netherlands, conducting research on drug discovery, pharmacology, and pharmaceutical sciences. UIPS studies include the pharmacokinetics, toxicology, and neurobiological effects of psychoactive compounds, and contributes to translational research bridging laboratory pharmacology and clinical application.
People
Search →Eduardo Schenberg
Neuroscientist and founder/director of Instituto Phaneros
A leading Brazilian psychedelic researcher known for clinical and translational work on ayahuasca, ibogaine, MDMA, and ethics/policy in psychedelic medicine.
Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Joost Breeksema
Postdoctoral researcher and Executive Director of the OPEN Foundation
He is a prominent psychedelic researcher and advocate whose work helps shape evidence-based psychedelic policy, ethics, and patient-centered understanding of psychedelic and ketamine/esketamine treatments.
Juliana Rocha
Doutoranda em Ciências Médicas / Saúde Mental at the Ribeirão Preto Medical School, University of São Paulo
She is a recurring coauthor on clinical psychedelic studies, especially ayahuasca trials on social anxiety, emotion recognition, personality, and social cognition, helping expand the human evidence base for psychedelic-assisted psychiatric research.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Jolien Veraart
Psychiatrist and PhD researcher at the University Medical Center Groningen / University of Groningen
She is a leading clinical researcher on ketamine and oral esketamine for treatment-resistant depression, including safety, efficacy, and real-world implementation.
Kate Godfrey
Research Associate at Imperial College London’s Centre for Psychedelic Research
Kate Godfrey is notable for contributing to leading human psychedelic research on microdosing, neuroimaging, and neuroplasticity at Imperial College London.
Joshua Di Vincenzo
MSc researcher / clinical research staff member at the University Health Network and University of Toronto
He coauthors multiple systematic reviews and real-world studies on ketamine for treatment-resistant depression, making him a visible contributor to the evidence base on psychedelic-adjacent psychiatric therapeutics.
John Kelly
Associate Professor / Consultant General Psychiatrist at Trinity College Dublin
John R. Kelly is a leading academic psychiatrist in Ireland whose work has helped shape modern psychedelic psychiatry, including psilocybin research across depression, service-user attitudes, and transdiagnostic treatment frameworks.
Kruti Joshi
Employee at Janssen Scientific Affairs, LLC
Joshi appears to be a Janssen-affiliated researcher coauthoring multiple real-world evidence studies on esketamine access, barriers, utilization, and economic outcomes in treatment-resistant depression.
David Mathai
Psychiatrist and Assistant Professor at The Johns Hopkins University School of Medicine
He is a psychiatric researcher at Johns Hopkins whose work spans psilocybin, ketamine/esketamine, and psychedelic-assisted psychotherapy, with multiple publications on experiential and therapeutic outcomes.
Connected Evidence
The latest clinical data and verified academic findings associated with Public Health, Prevention & Behaviour Change.